Targeted Therapies in Oncology Staff Writer
Articles by Targeted Therapies in Oncology Staff Writer

Updated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.

Four patients with lung adenocarcinoma with NRG1 fusions demonstrated some degree of response or tumor stabilization when given afatinib, according to a poster presentation at the 2019 World Conference on Lung Cancer meeting. The findings suggest that the irreversible pan-ERBB inhibitor is a potential treatment in this rare mutation of lung adenocarcinoma.

Findings from an interim analysis of the National Lung Matrix Trial, a large, multiarm trial involving patients with non–small cell lung cancer, demonstrated both promising activity and shortcomings in predefined goals in a presentation at the 2019 World Conference on Lung Cancer.

In a review of over 300 hematopoietic cell transplantation cases, thrombotic microangiopathy occurred in as many as 36% of patients and significantly raised the risk of related death, according to findings reported at the 2019 Transplantation and Cellular Therapy Meetings.

ASCO and SITC released a joint statement that outlines new recommendations for reporting data from immuno-oncology clinical trials.

Recent FDA drug approvals in hematologic malignancies have changed the treatment paradigm of many diseases and resulted in necessary updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

For clinicians who treat men with early-stage prostate cancer in their clinical practice, a new clinical guideline on the use of external beam radiation therapy has been developed by a panel of experts representing the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Urological Association.

Recent advancements in systemic therapies are changing the treatment landscape for patients with pancreatic cancer. New therapeutics and treatment strategies are emerging, meaning more patients than ever are candidates for curative procedures.